Three cheers for Myogen (MYOG). The company reported yesterday that the enoximone program, for the treatment of advanced stage chronic heart failure, has been terminated as a result of their two phase III trials failing to demonstrate a statistically significant benefit for any of the three co-primary endpoints. Despite the news something needs to be [...]